Key result
Reducing loop diuretics post-TAVR linked to ~54% lower HF rehospitalization risk in stable patients.
Why the study?
Large studies evaluating the safety of loop diuretic reduction in post-TAVR patients are lacking, and guidelines lack clear recommendations for diuretic adjustment despite potential adverse outcomes from continued use.
Does loop diuretics reduction reduce heart failure rehospitalization in stable patients post-TAVR?
Observational (n=29,358)
Yes
Does loop diuretics reduction reduce heart failure rehospitalization in stable patients post-TAVR?
Loop diuretic reduction at 90 days post-TAVR in stable patients is associated with a significantly lower risk of heart failure rehospitalization compared to continuing the same dose.
Answers are grounded in this paper and cite their sources.
Should not yet change post-TAVR diuretic management; hypothesis-generating in observational data, needs RCTs for confirmation.
Background Although transcatheter aortic valve replacement (TAVR) improves heart failure conditions for patients with severe aortic stenosis, more than 10% of patients have heart failure (HF) rehospitalization within 1 year. On the other hand, the continuation of loop diuretics (LD) may lead to adverse outcomes in patients with HF. However, large studies on the safety of LD reduction in post-TAVR patients with HF are lacking, and current guidelines do not provide clear recommendations for LD adjustment. This study investigated the impact of LD reduction on HF rehospitalization in post-TAVR patients using a nationwide database. Methods This retrospective observational study utilized data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) from 2014 to 2021. Patients without worsening HF following first-time TAVR were included. Patients were categorized into two groups according to the changes of LD dose at 90 days post-TAVR: Reduced LD group and non-Reduced LD group. The primary outcome was HF rehospitalization within two-years. We analyzed the association between the changes of LD dose and outcomes using inverse probability treatment weighting. Results Between April 2014 and March 2021, 29,358 patients without worsening HF at 90 days after TAVR were analyzed. Of these, 19,070 patients were not prescribed LD, 5,596 were in the Reduced LD group, and 4,692 were in the non-Reduced LD group. The Reduced LD group had a higher proportion of patients with a history of HF hospitalization, and the non-Reduced group had a higher proportion of comorbidities. The Reduced LD group had fewer HF rehospitalizations (HR 0.46, 95% CI: 0.41–0.51, P<.001) compared to the non-Reduced LD group. Conclusions Our study indicates that LD reduction was not associated with increased HF rehospitalization in stable HF patients after TAVR. LD reduction may be a viable option for consideration in such patients.
No takes yet. Share an insight, caveat, or question.
Takegawa et al. (2025) conducted an observational in Post-TAVR patients without worsening heart failure (n=29,358). Loop diuretics reduction vs. Non-reduced loop diuretics was evaluated on Heart failure rehospitalization within two-years (HR 0.46, 95% CI 0.41-0.51, p=<.001). Loop diuretics reduction at 90 days post-TAVR was associated with a lower risk of heart failure rehospitalization compared to non-reduction.
Synapse has enriched 10 related papers. Consider them for comparative context: